Abstract
This study reports on the uptake of 99mTc-RP527 by human breast carcinoma and its relationship to gastrin-releasing peptide receptor (GRP-R) expression as measured by immunohistochemistry (IHC). Methods: Nine patients referred because of a clinical diagnosis suggestive of breast carcinoma and 5 patients with tamoxifen-resistant bone-mestastasized breast carcinoma underwent 99mTc-RP527 scintigraphy. The findings were compared with routine staging examinations in all patients and with routine histology and IHC GRP-R staining in the first 9 patients. All 9 patients with suspected breast lesions were tumor positive. Results: The uptake of 99mTc-RP527 was evident in the primary tumor in 8 of 9 patients and in involved lymph nodes and part of the distant metastasis limited to the bone when present. 99mTc-RP527 uptake was not found in any of the tamoxifen-resistant patients. Conclusion: Uptake by primary breast carcinoma was significantly correlated with the presence of GRP-Rs as assessed by means of IHC. Copyright © 2008 by the Society of Nuclear Medicine, Inc.
Cite
CITATION STYLE
Van De Wiele, C., Phonteyne, P., Pauwels, P., Goethals, I., Van Den Broecke, R., Cocquyt, V., & Dierckx, R. A. (2008). Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. Journal of Nuclear Medicine, 49(2), 260–264. https://doi.org/10.2967/jnumed.107.047167
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.